CSANZ Logo
CSANZ Logo
Welcome to the official website of the


CSANZ Logo
CSANZ Logo
Cardiac Society of Australia and New Zealand
CSANZ Logo


CSANZ Logo


CSANZ Logo

contact
links
want to join?
register
search the CSANZ website
search the CSANZ website
     







search the CSANZ website













CSANZ Directory

CSANZ Member Directory

CSANZ Guidelines

Practice Guidelines

Training and Competence

Meetings

What's On and Where

ASM Abstracts Online

News and Views

Newsletter - On the Pulse

Newsletter - CNWG

In the News

Affiliate News
Career Opportunities

Affiliate Member Area

Affiliate Calendar

Affiliate Discussion

Scholarships/ Fellowships

Working Groups


ASM Abstracts

CHARACTERIZATION OF ALPHA1-ADRENOCEPTOR SUBTYPES IN HUMAN RADIAL, INTERNAL MAMMARY ARTERIES AND SAPHENOUS VEIN

M Yan* and Y L Lim.

National Heart Centre of Singapore and Department of Cardiology, Box Hill Hospital, Vic.

Spasm of the coronary bypass grafts using the radial artery (RA), internal mammary artery (IMA) and saphenous vein (SV) occurs in clinic. It appears that Alpha1-adrenoceptor (AR) is the main mediator of spasm in the human RA, IMA and SV.  We aimed to study the distribution of Alpha1-AR subtypes in these vessels since this information may have clinical significance in designing potential therapeutic targets for preventing spasm of coronary grafts.

The segments of blood vessels were obtained from 8 patients undergoing the bypass surgery. These patients were selected because they were not receiving any Alpha-AR agonists or antagonists. We examined the Alpha1-AR subtypes in RA, IMA and SV using reverse transcription polymerase chain reaction (RT-PCR), DNA-DNA hybridization analysis and functional affinities experiments. Using Alpha1A-, Alpha 1B- or Alpha1D-AR subtypes oligonucleotide primers sets to amplify human RA, IMA and SV cDNAs, DNA-DNA Hybridization was used to analyze PCR products. Cumulative concentration-response curves were constructed for noradrenaline Alpha-AR agonist)-induced contraction, and the effects of competitive antagonists were examined versus the potency in RA, IMA and SV.

The results are as follows: (1) The PCR products for Alpha1A-AR in RA and SV and Alpha1B-AR in IMA were observed, but Alpha1D-AR was not detectable in RA, IMA and SV. DNA-DNA hybridization confirmed the presence of Alpha1A-, Alpha1B- and Alpha1D-AR in RA, IMA and SV. (2) Prazosin, the a1-AR antagonist, phentolamine, a1- and a2-AR antagonist, 5-MU and WB4101, a1A-AR antagonists, were competitively antagonized the noradrenaline-induced contraction. The selective Alpha1D-AR antagonist BMY 7378 had a low affinity in RA, IMA and SV. Chloroethylclonidine, a a1B and a1D-AR antagonist, inhibited the noradrenaline-induced contraction in IMA and SV, but no effect in RA. Functional and binding affinities in RA, IMA and SV correlated well (Alpha1A r = 0.96 in RA; Alpha1B r = 0.91 in IMA; Alpha1A r = 0.89 and Alpha1B r = 0.98 in SV).

The results suggest that the Alpha1A-AR in RA, Alpha1B-AR in IMA and Alpha1A-and Alpha1B-ARs in SV is the main functional and expressed receptor subtypes.  These data emphases the need for prevention of catecholamine induced vasospasm, reinforcing consideration of Alpha1A antagonists to RA, Alpha1B antagonists to IMA, and Alpha1A and Alpha1B antagonists to SV, respectively, during and after coronary artery bypass surgery.

[ Back to 48th ASM Abstract Index ]


Med-E-Serv